2 YEARS OF EXPERIENCE
2 YEARS OF EXPERIENCE

For postmenopausal women
with a recent osteoporotic fracture:
Help change the course of
postmenopausal osteoporosis
at 18 months with TYMLOS2

TYMLOS, an anabolic agent for postmenopausal osteoporosis, demonstrated2,3:

  • 86% relative risk reduction (RRR) in new vertebral fractures vs placebo (P<0.0001) and 3.6% absolute risk reduction (ARR) at 18 months2
  • 43%RRR in nonvertebral fractures vs placebo (P=0.049)
    and 2.0% ARR at 19 months2†

Data current as of April 2019.1

Data included 18 months of treatment plus 1 month without treatment; P value
based on the log-rank test.2

Download resources to help
patients get access
to
TYMLOS treatment

Learn about efficacy results that were maintained with sequential therapy

Watch the abaloparatide
mechanism of
action video

References: 1. Data on file. Radius Health, Inc; Waltham, MA. 2. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2018. 3. Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-317.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.   All rights reserved.    05/19.   TYM-US-02572

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2019 Radius Health, Inc.
All rights reserved. 05/19.
TYM-US-02572

Back to Top